Canadian Journal of Urology最新文献_第3页

Renal cell carcinoma: entering the age of biomarkers. 肾细胞癌：进入生物标志物时代。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Andrew S Iskandar, Kevin K Zarrabi, William J Tester

{"title":"Renal cell carcinoma: entering the age of biomarkers.","authors":"Andrew S Iskandar, Kevin K Zarrabi, William J Tester","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference biomarkers of interest in this domain. We selected studies based on their relevance, publication date, and the quality of the research. Data from these selected papers were compiled and analyzed to provide an overview of the current understanding and advancements in the field. The findings were then synthesized into a concise discussion highlighting the state of biomarker research in renal cell carcinoma today.Results and conclusions: While various nucleic acid and protein biomarkers have shown promise in other malignancies, their application in renal cell carcinoma remains limited by the lack of validated predictors. This review aims to highlight the pressing need for robust predictive and prognostic biomarkers in renal cell carcinoma to guide clinicians in tailoring optimal therapeutic strategies. The discussion encompasses the limitations of existing markers and underscores the significance of the most recent advancements within the field. Despite these strides, the clinical application of renal cell carcinoma biomarkers requires further study and validation.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11921-11930"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Motivation toward vasectomy based on abortion law changes in Oklahoma. 基于俄克拉荷马州堕胎法修改的输精管切除动机。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Hope Ogbeide, Ehidiamen Oamen, Travis H Wilmore, Jennifer D Peck, Johnathan P Doolittle, Nathan A Bradley, Jonathan E Heinlen

{"title":"Motivation toward vasectomy based on abortion law changes in Oklahoma.","authors":"Hope Ogbeide, Ehidiamen Oamen, Travis H Wilmore, Jennifer D Peck, Johnathan P Doolittle, Nathan A Bradley, Jonathan E Heinlen","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: In May 2022, lawmakers in Oklahoma passed House Bill 4327, which outlawed abortion after fertilization. The governor signed the bill on May 25, 2022. It is uncertain whether these changes will motivate more men in Oklahoma to undergo vasectomy.Materials and methods: Males seeking vasectomy were informed of the study and asked to participate. Participants filled out a survey regarding their marital status, number of children, fertility treatment history, and their influences in making the decision to pursue vasectomy. We removed the identifying information from the survey. After collection, the data was imported to a database. Medical records were investigated to confirm patients underwent the procedure.Results: Of the 126 participants, 116 underwent vasectomy. Patients who did not undergo vasectomy tended to be older (38.4 vs. 34.2, p = 0.03). Participants who underwent vasectomy and were concerned about abortion laws tended to be married (69.7 vs. 30.3%, p = 0.04) with fewer children (1.2 vs. 2.3, p < 0.0001). When correlating specifically \"concern about abortion laws\" and going through with vasectomy, the risk ratio of 1.12 (95% CI 1.04, 1.20) indicates that patients concerned about abortion laws were slightly more likely to undergo vasectomy.Conclusions: Over 26% of men said that their decisions were somewhat impacted by abortion law changes. The concern about abortion law changes seemed to be predictive of patients undergoing vasectomy. Continued data collection will help determine whether there is a time-sensitive nature regarding the impact of abortion law changes on motivation to vasectomy.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11950-11954"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is there a relationship between testosterone and androgen receptor with prostatectomy outcomes? 睾酮和雄激素受体与前列腺切除术的结果有关系吗？

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Bárbara Vieira Lima Aguiar Melão, Sabrina Thalita Dos Reis Faria, Kátia Ramos Moreira Leite, Ruan César Aparecido Pimenta, Miguel Srougi, Alberto Azoubel Antunes

{"title":"Is there a relationship between testosterone and androgen receptor with prostatectomy outcomes?","authors":"Bárbara Vieira Lima Aguiar Melão, Sabrina Thalita Dos Reis Faria, Kátia Ramos Moreira Leite, Ruan César Aparecido Pimenta, Miguel Srougi, Alberto Azoubel Antunes","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Prostate cancer has a variable natural history and, despite the existence of biochemical recurrence (BCR) predictors, they are still limited in predicting outcomes. The role of testosterone in advanced prostate cancer is well known, however its role in localized prostate cancer is still uncertain. In the present study, we evaluated the relationship of testosterone levels and androgen receptor (AR) expression with oncological and functional outcomes, in patients undergoing radical retropubic prostatectomy (RRP).Materials and methods: Through a retrospective study, patients who underwent RRP, who had at least two preoperative total testosterone dosages, were analyzed and compared according to testosterone levels, oncological and functional outcomes. After analyzing data, tissue samples were selected in a biorepository to carry out the AR and the AR-V7 expression.Results: After applying exclusion criteria, 212 patients were included in the analysis. Thirty-two patients (15.1%) had low testosterone levels and, in this group, a lower rates of erectile function recovery were observed at 24 months (53.1% vs. 71.7%; p = 0.037), a higher rate of BCR (21.9% vs. 9.4%; p = 0.041) and higher International Society of Urological Pathology (ISUP) grade in biopsy products. The AR expression was higher in patients with low testosterone, but there was no difference in relapse rates.Conclusions: Lower levels of testosterone were related to lower rates of erectile function recovery at the end of 24 months after RRP, in addition to conferring higher rates of BCR and higher ISUP grades in biopsy. Furthermore, patients with total testosterone < 300 ng/dL had higher expression of AR, but no difference in BCR rates.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11931-11940"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer. 基于磁共振成像的PI-RADS评分可预测ISUP升级和前列腺癌根治术时的不良病理结果。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Snir Dekalo, Ohad Mazliah, Eyal Barkai, Yuval Bar-Yosef, Haim Herzberg, Tomer Bashi, Ibrahim Fahoum, Sophie Barnes, Mario Sofer, Ofer Yossepowitch, Gal Keren-Paz, Roy Mano

{"title":"MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer.","authors":"Snir Dekalo, Ohad Mazliah, Eyal Barkai, Yuval Bar-Yosef, Haim Herzberg, Tomer Bashi, Ibrahim Fahoum, Sophie Barnes, Mario Sofer, Ofer Yossepowitch, Gal Keren-Paz, Roy Mano","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Most men diagnosed with very-low and low-risk prostate cancer are candidates for active surveillance; however, there is still a misclassification risk. We examined whether PI-RADS category 4 or 5 combined with ISUP 1 on prostate biopsy predicts upgrading and/or adverse pathology at radical prostatectomy.Materials and methods: A total of 127 patients had ISUP 1 cancer on biopsy after multiparametric MRI (mpMRI) and then underwent radical prostatectomy. We then evaluated them for ISUP upgrading and/or adverse pathology on radical prostatectomy.Results: Eight-nine patients (70%) were diagnosed with PI-RADS 4 or 5 lesions. ISUP upgrading was significantly higher among patients with PI-RADS 4-5 lesions (84%) compared to patients with equivocal or non-suspicious mpMRI findings (26%, p < 0.001). Both PI-RADS 4-5 lesions (OR 24.3, 95% CI 7.3, 80.5, p < 0.001) and stage T2 on DRE (OR 5.9, 95% CI 1.2, 29.4, p = 0.03) were independent predictors of upgrading on multivariate logistic regression analysis. Men with PI-RADS 4-5 lesions also had significantly more extra-prostatic extension (51% vs. 3%, p < 0.001) and positive surgical margins (16% vs. 3%. p = 0.03). The only independent predictor of adverse pathology was PI-RADS 4-5 (OR 21.7, 95% CI 4.8, 99, p < 0.001).Conclusion: PI-RADS 4 or 5 lesions on mpMRI were strong independent predictors of upgrading and adverse pathology. Incorporating mpMRI findings when selecting patients for active surveillance must be further evaluated in future studies.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11955-11962"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

President's Message Mid-Atlantic Section of the AUA 2024. 主席致辞美国建筑学会大西洋中部分会 2024 年。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

B Mayer Grob

引用次数: 0

Legends in Urology v31I04. 泌尿外科传奇》第 31I04 期。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Jerry G Blaivas

引用次数: 0

Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence. 膀胱过度活动症、慢性骨盆疼痛和大便失禁男性患者的骶神经调节疗效。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Roseanne Ferreira, Emad Alwashmi, Samuel Otis-Chapados, Naeem Bhojani, Kevin C Zorn, Bilal Chughtai, Dean S Elterman

{"title":"Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence.","authors":"Roseanne Ferreira, Emad Alwashmi, Samuel Otis-Chapados, Naeem Bhojani, Kevin C Zorn, Bilal Chughtai, Dean S Elterman","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Despite the growing body of literature on sacral neuromodulation (SNM) outcomes, research focusing on male patients remains limited and often represented by small cohorts nested within a larger study of mostly women. Herein, we evaluated the outcomes of SNM in a male-only cohort with overactive bladder (OAB), fecal incontinence (FI), chronic bladder pain, and neurogenic lower urinary tract dysfunction (NLUTD).Materials and methods: This retrospective cohort study included 64 male patients who underwent SNM insertion between 2013 and 2021 at a high-volume tertiary center. Indications for SNM therapy included OAB, FI, chronic pelvic pain, and NLUTD. Descriptive statistics, Fisher's and t-test were used in analysis.Results: The mean age was 57.7 ± 13.4 years, and the most frequent reason for SNM insertion was idiopathic OAB (72%), FI (16%), pelvic pain (11%), and NLUTD (11%). A majority (84%) of men received treatment prior to SNM insertion. 84% reported satisfaction and 92% symptom improvement within the first year, and these improvements persisted beyond 1 year in 73% of patients. Mean follow up was 52.7 ± 21.0 months. The complication rate was 23%, and the need for adjunct treatments was significantly reduced (73% to 27%, p < 0.001). Treatment outcomes did not differ significantly between various indications for SNM therapy or the presence of benign prostatic hyperplasia (BPH).Conclusion: SNM is an effective and safe procedure for male patients with neurogenic and non-neurogenic OAB, pelvic pain, and FI. Over 70% of patients experienced symptomatic improvement and remained satisfied in the mid to long term follow up. BPH does not seem to hinder treatment outcomes.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11943-11949"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate cancer and testosterone: what does the prostate cancer surgeon need to know? 前列腺癌与睾酮：前列腺癌外科医生需要了解什么？

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Judd W Moul

引用次数: 0

A costing and health-related quality of life study of high intensity focused ultrasound in primary treatment of localized low or intermediate risk prostate cancer in Ontario. 安大略省高强度聚焦超声波用于局部低危或中危前列腺癌初级治疗的成本核算和健康相关生活质量研究。

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-08-01

Bassem Toeama, Nathan Perlis, Paul Grootendorst, William Orovan, Emmanuel Papadimitropoulos

{"title":"A costing and health-related quality of life study of high intensity focused ultrasound in primary treatment of localized low or intermediate risk prostate cancer in Ontario.","authors":"Bassem Toeama, Nathan Perlis, Paul Grootendorst, William Orovan, Emmanuel Papadimitropoulos","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Prostate cancer is the third leading cause of death from cancer among Canadian men. High intensity focused ultrasound (HIFU) is a novel approach for primary treatment of localized prostate cancer. Little is known, however, about its costs. We aimed to collect the direct costs and health-related quality of life (HRQoL) data of HIFU in primary treatment of localized low and intermediate risk prostate cancer in Ontario.Materials and methods: We collected direct costs and HRQoL data of 20 patients with localized low or intermediate risk prostate cancer who received whole-gland HIFU at a privately owned clinic in Ontario. We compared the direct costs of HIFU, open radical prostatectomy (ORP), robot assisted radical prostatectomy (RARP), and external beam radiation therapy (RT) in primary treatment of localized low and intermediate risk prostate cancer.Results: The average direct costs of HIFU, ORP, RARP, and RT per case in 2023 are $14,886.78, $14,192.26, $21,794.55, and $17,377.51, respectively. The median and interquartile range (IQR) of the study participants' age and HRQoL data prior to the HIFU procedure were 64.5 (11.25) years, 94.5 (8.65), 38.5 (4), 6.0 (4.46), and 22.5 (8.32), respectively.Conclusion: Our healthcare payer's perspective costing study revealed median direct costs per case of HIFU and favorable HRQoL outcomes compared to other treatment options for primary treatment of localized low and intermediate risk prostate cancer in Ontario. A health economic model is warranted to analyze the cost-effectiveness of HIFU compared to other treatment options in primary treatment of localized low and intermediate risk prostate cancer.","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 4","pages":"11963-11970"},"PeriodicalIF":1.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Review - Proctor JG. Pentosan polysulfate and a pigmentary maculopathy: causation versus correlation? 关于评论 - Proctor JG.多硫酸戊聚糖与色素性黄斑病变：因果关系还是相关关系？

IF 1.2 4区医学

Canadian Journal of Urology Pub Date : 2024-06-01

Jenelle Foote, Sakshi Shiromani, Nieraj Jain

引用次数: 0